RxDoctor Payments Data

Aaron Reinke, MD

Family Medicine · Newport, WANPI 1063823375

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 95 payments — averaging $12.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$216
  • Johnson & Johnson$162
  • Sanofi-aventis U.S. LLC$123
  • Boehringer Ingelheim$78
  • GSK$75
  • AstraZeneca$74
  • plus $437 from 11 others

What the payments were for

  • Food & beverage$1,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,166 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$11,052
Medicare patients
33
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$143,554
JardianceEmpagliflozin81$82,511
EliquisApixaban57$51,269
XareltoRivaroxaban39$35,171
FarxigaDapagliflozin Propanediol39$25,800
MounjaroTirzepatide20$24,649
Tresiba Flextouch U-100Insulin Degludec40$19,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,223
MyrbetriqMirabegron24$11,014
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$10,538
EntrestoSacubitril/Valsartan13$9,782
Spiriva HandihalerTiotropium Bromide12$5,886
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,207
Incruse ElliptaUmeclidinium Bromide11$4,313
Aripiprazole35$3,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$216$143,554132 claims
Boehringer IngelheimJardiance$78$82,51181 claims
PfizerEliquis$51$51,26957 claims
Johnson & JohnsonXarelto$162$35,17139 claims
AstraZenecaFarxiga, Symbicort$74$27,92251 claims
Lilly USA, LLCMounjaro$69$24,64920 claims
GSKTrelegy Ellipta, Incruse Ellipta$75$23,53637 claims
Astellas Pharma US IncMyrbetriq$72$11,01424 claims
NovartisEntresto$21$9,78213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Newport

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →